title: The safety and utility of prophylactic pancreatic duct stents in the prevention of post-ERCP pancreatitis: an analysis of practice in a single UK tertiary referral center.
abstract: BACKGROUND
  The use of temporary prophylactic pancreatic duct (PD) stents in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in high-risk patients has been shown to be effective in multiple trials. However, there are limited data on the clinical implications of PD stents and their impact on practice outside of the trial setting.
  
  
  METHODS
  The utility of prophylactic pancreatic stenting was evaluated in a retrospective analysis of 1,000 consecutive ERCPs performed in a single tertiary referral pancreatobiliary center over a 24-month period, based upon a predetermined protocol to identify patients at high risk of postprocedure pancreatitis.
  
  
  RESULTS
  One thousand procedures performed in 688 patients were studied. Sixty-one patients were considered for stent placement and stents were successfully placed in 58 cases. The overall rate of post-ERCP pancreatitis in our study population was 3.6%. The rate of pancreatitis in the stented patients was considered high at 22.4%, but the majority (69%) were classified as mild and there were no reported severe episodes. This compares to pancreatitis in the nonstented group, in whom the majority (73.9%) experienced either moderate or severe episodes.
  
  
  CONCLUSIONS
  A strategy of prophylactic PD stents in this study has eliminated severe post-ERCP pancreatitis in high-risk patients. However, the high pancreatitis rate in stented patients may represent the cost to achieve this, while stent type and size employed are likely contributing factors. To maximize the benefits of PD stenting, there is a need to identify and treat all those considered at high risk.
authors.affiliation: Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
authors.forename: Patrick T F
authors.initials: PT
authors.lastname: Kennedy
authors.forename: Evangelos
authors.initials: E
authors.lastname: Russo
authors.forename: Naveenta
authors.initials: N
authors.lastname: Kumar
authors.forename: Nick
authors.initials: N
authors.lastname: Powell
authors.forename: Devinder
authors.initials: D
authors.lastname: Bansi
authors.forename: Andrew
authors.initials: A
authors.lastname: Thillainayagam
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Vlavianos
authors.forename: David
authors.initials: D
authors.lastname: Westaby
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000209:etiology* / Q000517:prevention & control*; D012017:Referral and Consultation; D012189:Retrospective Studies; D012449:Safety; D015607:Stents; D006113:United Kingdom; D055815:Young Adult